Patients Stable on Sublocade Face Forced Switch to Daily Opioid Treatments

Indivior is withdrawing Sublocade, a monthly buprenorphine injection, from Australia by end-2026. The drug was designed precisely to avoid the adherence failures of daily sublingual buprenorphine. Patients already stabilized on Sublocade—especially those with poor compliance histories—must transition to daily pills or methadone. Buvidal, a competing weekly-monthly depot, offers partial substitution but not therapeutic equivalence for all patients. Clinicians face case-by-case management and real clinical risk during transition.